Cervical Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Cervical Cancer, including details on symptoms, vaccine, screening, treatment, human papilloma virus (hpv), information.

Volume 2 (2005), Issue 4 (April)

1. Immunohistochemical expression of p16INK4a and bcl-2 according to HPV type and to the progression of cervical squamous intraepithelial lesions.
   J Histochem Cytochem, 53(4): 509-16. [Abstract] [Full-text]
2. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma.
   Cancer Res, 65(7): 2921-9. [Abstract] [Full-text]
3. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci.
   J Exp Med, 201(7): 1069-75. [Abstract] [Full-text]
4. Microregional expression of glucose transporter-1 and oxygenation status: lack of correlation in locally advanced cervical cancers.
   Clin Cancer Res, 11(7): 2768-73. [Abstract] [Full-text]
5. Increased apoptosis in cervical intraepithelial neoplasia associated with HIV infection: implication of oncogenic human papillomavirus, caspases, and Langerhans cells.
   Clin Cancer Res, 11(7): 2451-8. [Abstract] [Full-text]
6. Inhibitory effect of jaceosidin isolated from Artemisiaargyi on the function of E6 and E7 oncoproteins of HPV 16.
   J Ethnopharmacol, 98(3): 339-43. [Abstract] [Full-text]
7. Risk of invasive cervical cancer after Pap smears: the protective effect of multiple negatives.
   J Med Screen, 12(1): 7-11. [Abstract] [Full-text]
8. TRAIL is a key target in S-phase slowing-dependent apoptosis induced by interferon-beta in cervical carcinoma cells.
   Oncogene, 24(15): 2536-46. [Abstract] [Full-text]
9. Constitutively active Notch1 induces growth arrest of HPV-positive cervical cancer cells via separate signaling pathways.
   Exp Cell Res, 305(2): 343-54. [Abstract] [Full-text]
10. Feasibility of radical surgery in the management of elderly patients with uterine cervical cancer in Korea.
    Gynecol Obstet Invest, 59(3): 165-70. [Abstract] [Full-text]
11. Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/ 5-fluorouracil in recurrent cervical cancer.
    Gynecol Obstet Invest, 59(3): 126-9. [Abstract] [Full-text]
12. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations.
    Immunology, 115(1): 136-49. [Abstract] [Full-text]
13. Preventing cervical cancer in low-resource settings: how far have we come and what does the future hold?
    Int J Gynaecol Obstet, 89: S55-9. [Abstract] [Full-text]
14. Advocating for cervical cancer prevention.
    Int J Gynaecol Obstet, 89: S46-54. [Abstract] [Full-text]
15. A critical assessment of screening methods for cervical neoplasia.
    Int J Gynaecol Obstet, 89: S4-S12. [Abstract] [Full-text]
16. Involving the community in cervical cancer prevention programs.
    Int J Gynaecol Obstet, 89: S38-45. [Abstract] [Full-text]
17. Training for cervical cancer prevention programs in low-resource settings: focus on visual inspection with acetic acid and cryotherapy.
    Int J Gynaecol Obstet, 89: S30-7. [Abstract] [Full-text]
18. Delivering cervical cancer prevention services in low-resource settings.
    Int J Gynaecol Obstet, 89: S21-9. [Abstract] [Full-text]
19. Experience using cryotherapy for treatment of cervical precancerous lesions in low-resource settings.
    Int J Gynaecol Obstet, 89: S13-20. [Abstract] [Full-text]
20. A systematic nerve-sparing radical hysterectomy technique in invasive cervical cancer for preserving postsurgical bladder function.
    Int J Gynecol Cancer, 15(2): 389-97. [Abstract] [Full-text]
21. A case with multiple gynecological malignancies.
    Int J Gynecol Cancer, 15(2): 372-6. [Abstract] [Full-text]
22. Villoglandular adenocarcinoma of the cervix recurrent in an episiotomy scar: a case report in a 32-year-old female.
    Int J Gynecol Cancer, 15(2): 366-71. [Abstract] [Full-text]
23. Epstein-Barr virus plays little role in cervical carcinogenesis in Korean women.
    Int J Gynecol Cancer, 15(2): 312-8. [Abstract] [Full-text]
24. Microsatellite instability is not related to response to cisplatin-based chemotherapy in cervical cancer.
    Int J Gynecol Cancer, 15(2): 308-11. [Abstract] [Full-text]
25. Antiproliferative activity and toxicity of 2-methoxyestradiol in cervical cancer xenograft mice.
    Int J Gynecol Cancer, 15(2): 301-7. [Abstract] [Full-text]
26. Small-cell carcinoma of the uterine cervix: a clinicopathologic study of 11 cases.
    Int J Gynecol Cancer, 15(2): 295-300. [Abstract] [Full-text]
27. Evaluation of cytologic screening results of the cervix.
    Int J Gynecol Cancer, 15(2): 292-4. [Abstract] [Full-text]
28. Adjuvant radiotherapy in carcinomas of the uterine cervix: the prognostic value of hemoglobin levels.
    Int J Gynecol Cancer, 15(2): 285-91. [Abstract] [Full-text]
29. Human papillomavirus status in advanced cervical cancer: predictive and prognostic significance for curative radiation treatment.
    Int J Gynecol Cancer, 15(2): 278-84. [Abstract] [Full-text]
30. Sentinel node detection with radiocolloid lymphatic mapping in early invasive cervical cancer.
    Int J Gynecol Cancer, 15(2): 273-7. [Abstract] [Full-text]
31. Information given to women invited for cervical screening: results of two postal surveys seven years apart.
    Int J Gynecol Cancer, 15(2): 267-72. [Abstract] [Full-text]
32. CD109 expression in squamous cell carcinoma of the uterine cervix.
    Pathol Int, 55(4): 165-9. [Abstract] [Full-text]
33. HPV in situ hybridization: impact of different protocols on the detection of integrated HPV.
    Int J Cancer, 115(3): 419-28. [Abstract] [Full-text]
34. Evaluation of a digital store-and-forward colposcopic system--a pilot study to assess usability for telemedicine.
    J Telemed Telecare, 11(2): 103-7. [Abstract] [Full-text]
35. Quality and efficacy of a telecolposcopy programme.
    J Telemed Telecare, 11(1): 20-2. [Abstract] [Full-text]
36. 'Have a Pap smear!'--doctors, their clients, and opportunistic cervical cancer screening.
    Int J STD AIDS, 16(3): 233-6. [Abstract] [Full-text]
37. Aberrant, highly hyperdiploid cells in human papillomavirus-positive, abnormal cytologic samples are associated with progressive lesions of the uterine cervix.
    Cancer, 105(2): 96-100. [Abstract] [Full-text]
38. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer.
    J Clin Oncol, 23(12): 2813-21. [Abstract] [Full-text]
39. Survival in cervix cancer patients treated with radiotherapy followed by radical surgery.
    Eur J Surg Oncol, 31(4): 424-33. [Abstract] [Full-text]
40. Noncorrelating Pap tests and cervical biopsies: histological predictors of subsequent correlation.
    Diagn Cytopathol, 32(5): 310-4. [Abstract] [Full-text]
41. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women.
    J Natl Cancer Inst, 97(8): 577-86. [Abstract] [Full-text]
42. Papanicolaou screening in an urgent care setting.
    Am J Obstet Gynecol, 192(4): 1084-6. [Abstract] [Full-text]
43. Multimodal treatment of locally advanced cervical cancer.
    Arch Med Res, 36(2): 129-35. [Abstract] [Full-text]
44. Visual inspection with acetic acid and cytology as screening methods for cervical lesions in Cameroon.
    Int J Gynaecol Obstet, 89(2): 167-73. [Abstract] [Full-text]
45. Comparison of pap smear, visual inspection with acetic acid, human papillomavirus DNA-PCR testing and cervicography.
    Int J Gynaecol Obstet, 89(2): 120-6. [Abstract] [Full-text]
46. Comparison between CT-based volumetric calculations and ICRU reference-point estimates of radiation doses delivered to bladder and rectum during intracavitary radiotherapy for cervical cancer.
    Int J Radiat Oncol Biol Phys, 62(1): 131-7. [Abstract] [Full-text]
47. High-dose-rate brachytherapy in uterine cervical carcinoma.
    Int J Radiat Oncol Biol Phys, 62(1): 125-30. [Abstract] [Full-text]
48. Fractionated stereotactic radiotherapy boost for gynecologic tumors: an alternative to brachytherapy?
    Int J Radiat Oncol Biol Phys, 62(1): 118-24. [Abstract] [Full-text]
49. Pap smear use in California: are we closing the racial/ethnic gap?
    Prev Med, 40(6): 747-55. [Abstract] [Full-text]
50. Proteomic analysis of progressive factors in uterine cervical cancer.
    Proteomics, 5(6): 1481-93. [Abstract] [Full-text]
51. Radiological features of adenoid cystic carcinoma of the uterine cervix.
    Eur Radiol, 15(5): 975-7. [Abstract] [Full-text]
52. p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer.
    J Clin Pathol, 58(5): 525-34. [Abstract] [Full-text]
53. Association between the stages of cervical cancer and chromosome 1 aneusomy.
    Cancer Genet Cytogenet, 159(1): 44-7. [Abstract] [Full-text]

© 2004-2008 Cervical Cancer Research Today. All Rights Reserved.